Literature DB >> 12904197

Serious overdoses involving buprenorphine in Helsinki.

J Boyd1, T Randell, H Luurila, M Kuisma.   

Abstract

BACKGROUND: Buprenorphine is used as maintenance therapy for opioid-dependent patients. In comparison with other opioids it is thought to be safer because it is less likely to cause serious respiratory depression. However, concomitant use of psychotropics, especially benzodiazepines, and intravenous injection of dissolved buprenorphine tablets increase the risk of a serious overdose.
METHODS: As part of a larger retrospective study of opioid overdoses in Helsinki, the emergency medical services (EMS) records from January 1995 to April 2002 were reviewed for overdoses involving buprenorphine. Hospital records were reviewed when available.
RESULTS: We report 11 overdoses in which buprenorphine was involved. The classic symptoms and signs of an opioid overdose (respiratory depression, miosis and central nervous system depression) were present in most of the cases. At least eight of the patients had an overdose that was potentially fatal. One of the patients had a heroin overdose and was reportedly 'treated' by his friends with intravenously administered buprenorphine.
CONCLUSION: The high-dosage formulation of buprenorphine used for opioid-dependent patients might have caused several dangerous and potentially fatal overdoses in Helsinki. However, it does cause considerably less serious overdoses than heroin. Drug abusers might be intravenously administering buprenorphine themselves to treat heroin overdoses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12904197     DOI: 10.1034/j.1399-6576.2003.00201.x

Source DB:  PubMed          Journal:  Acta Anaesthesiol Scand        ISSN: 0001-5172            Impact factor:   2.105


  13 in total

1.  An in vitro approach to estimate putative inhibition of buprenorphine and norbuprenorphine glucuronidation.

Authors:  Stephanie Oechsler; Gisela Skopp
Journal:  Int J Legal Med       Date:  2010-01-29       Impact factor: 2.686

2.  Disparity in naloxone administration by emergency medical service providers and the burden of drug overdose in US rural communities.

Authors:  Mark Faul; Michael W Dailey; David E Sugerman; Scott M Sasser; Benjamin Levy; Len J Paulozzi
Journal:  Am J Public Health       Date:  2015-04-23       Impact factor: 9.308

3.  Intravenous use of illicit buprenorphine/naloxone to reverse an acute heroin overdose.

Authors:  Michael A Yokell; Nickolas D Zaller; Traci C Green; Michelle McKenzie; Josiah D Rich
Journal:  J Opioid Manag       Date:  2012 Jan-Feb

4.  Effect of psychotropic medication on the in vitro metabolism of buprenorphine in human cDNA-expressed cytochrome P450 enzymes.

Authors:  Stephanie Bomsien; Rolf Aderjan; Rainer Mattern; Gisela Skopp
Journal:  Eur J Clin Pharmacol       Date:  2006-06-27       Impact factor: 2.953

5.  Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes.

Authors:  Yan Chang; David E Moody
Journal:  Eur J Clin Pharmacol       Date:  2005-01-19       Impact factor: 2.953

Review 6.  Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

Review 7.  Buprenorphine: new treatment of opioid addiction in primary care.

Authors:  Meldon Kahan; Anita Srivastava; Alice Ordean; Sharon Cirone
Journal:  Can Fam Physician       Date:  2011-03       Impact factor: 3.275

8.  Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.

Authors:  Kirsten E Smith; Martha D Tillson; Michele Staton; Erin M Winston
Journal:  Drug Alcohol Depend       Date:  2020-01-09       Impact factor: 4.492

Review 9. 

Authors:  Anita Srivastava; Meldon Kahan; Maya Nader
Journal:  Can Fam Physician       Date:  2017-03       Impact factor: 3.275

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.